Skip to main content

Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline

By: Newsfile

Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the release of a thematic report that examines small market cap pharmaceutical companies based on revenue growth and valuation. The report: Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline examines that represents the top 0.1 percentile of small pharmaceutical growth companies.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • The market intelligence report identifies a group of small-cap healthcare companies that we believe represent small, undervalued businesses with room to grow in the current biotech industry downturn.
  • The report highlights standout companies including -- Alimera Sciences, Inc. (NASDAQ: ALIM), Assertio Holdings, Inc. (NASDAQ: ASRT), Aytu BioPharma, Inc. (NASDAQ: AYTU), Evolus, Inc. (NASDAQ: EOLS), and Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) -- that not only show strong revenue growth but also low enterprise value to sales ratios.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/176474_figure1_550.jpg

Click image above to view full announcement.


About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking, equity research and capital raising for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/176474

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.